Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Tharcila V. Chaves, Bob Wilffert & Zila M. Sanchez. (2023) Overdoses and deaths related to the use of ketamine and its analogues: a systematic review. The American Journal of Drug and Alcohol Abuse 49:2, pages 141-150.
Read now
Read now
Laura Orsolini, Virginio Salvi & Umberto Volpe. (2022) Craving and addictive potential of esketamine as side effects?. Expert Opinion on Drug Safety 21:6, pages 803-812.
Read now
Read now
Hongjuan Dong, Shanghua Fan, Ying Luo & Bin Peng. (2019) Botulinum toxin relieves anxiety and depression in patients with hemifacial spasm and blepharospasm. Neuropsychiatric Disease and Treatment 15, pages 33-36.
Read now
Read now
Jennifer Swainson, Rejish K Thomas, Shaina Archer, Carson Chrenek, Mary-Anne MacKay, Glen Baker, Serdar Dursun, Larry J. Klassen, Pratap Chokka & Michael L Demas. (2019) Esketamine for treatment resistant depression. Expert Review of Neurotherapeutics 19:10, pages 899-911.
Read now
Read now
Matthew W. Johnson. (2018) Psychiatry might need some psychedelic therapy. International Review of Psychiatry 30:4, pages 285-290.
Read now
Read now
Articles from other publishers (19)
Rute Dinis Sousa, Miguel Gouveia, Catarina Nunes da Silva, Ana Maria Rodrigues, Graça Cardoso, Ana Filipa Antunes, Helena Canhao & José Miguel Caldas de Almeida. (2022) Treatment-resistant depression and major depression with suicide risk—The cost of illness and burden of disease. Frontiers in Public Health 10.
Crossref
Crossref
AmirMohammad Sharafi, Sina Pakkhesal, Ali Fakhari, Nazli Khajehnasiri & Ali Ahmadalipour. (2022) Rapid treatments for depression: Endocannabinoid system as a therapeutic target. Neuroscience & Biobehavioral Reviews 137, pages 104635.
Crossref
Crossref
J.S. Wei, X. Hu, L. Xia, J. Shang, Q. Han & D.Y. Zhang. (2022) Evaluation of the effect of botulinum toxin A on the physical and mental health of patients with hemifacial spasm. Neurología.
Crossref
Crossref
Zach Walsh, Ozden Merve Mollaahmetoglu, Joseph Rootman, Shannon Golsof, Johanna Keeler, Beth Marsh, David J. Nutt & Celia J. A. Morgan. (2021) Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review. BJPsych Open 8:1.
Crossref
Crossref
Dusan Kolar & Michael V. Kolar. (2021) Alertness in patients with treatment-resistant depression: interface between sleep medicine and psychiatry—review article. Middle East Current Psychiatry 28:1.
Crossref
Crossref
Rodrigo P. Mello, Mariana V.F. Echegaray, Ana Paula Jesus-Nunes, Gustavo C. Leal, Guilherme M. Magnavita, Flávia Vieira, Ana Teresa Caliman-Fontes, Manuela Telles, Lívia N.F. Guerreiro-Costa, Breno Souza-Marques, Igor D. Bandeira, Cassio Santos-Lima, Roberta F. Marback, Fernanda S. Correia-Melo, Acioly L.T. Lacerda & Lucas C. Quarantini. (2021) Trait dissociation as a predictor of induced dissociation by ketamine or esketamine in treatment-resistant depression: Secondary analysis from a randomized controlled trial. Journal of Psychiatric Research 138, pages 576-583.
Crossref
Crossref
Jin Wang, Jing Tang, Xin Liang, Yanmin Luo, Peilin Zhu, Yue Li, Kai Xiao, Lin Jiang, Hao Yang, Yuhan Xie, Lei Zhang, Yuhui Deng, Jing Li & Yong Tang. (2021) Hippocampal PGC-1α-mediated positive effects on parvalbumin interneurons are required for the antidepressant effects of running exercise. Translational Psychiatry 11:1.
Crossref
Crossref
Sari Goldstein Ferber, Viviana Trezza & Aron Weller. (2019) Early life stress and development of the endocannabinoid system: A bidirectional process in programming future coping. Developmental Psychobiology 63:2, pages 143-152.
Crossref
Crossref
Walter S. Marcantoni, Bertine Sandra Akoumba, Maggy Wassef, Julie Mayrand, Hinatea Lai, Stéphane Richard-Devantoy & Sylvie Beauchamp. (2020) A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009 – January 2019. Journal of Affective Disorders 277, pages 831-841.
Crossref
Crossref
Dusan Kolar. (2020) Long-term treatment of depression with intranasal esketamine: Is it justified?. Asian Journal of Psychiatry 54, pages 102232.
Crossref
Crossref
Matthew H. Bilhimer, Meghan E. Groth & Ashley K. Holmes. (2020) Ketamine for Migraine in the Emergency Department. Advanced Emergency Nursing Journal 42:2, pages 96-102.
Crossref
Crossref
Lian‐Yu Chen, Chih‐Ken Chen, Chun‐Hsin Chen, Hu‐Ming Chang, Ming‐Chyi Huang & Ke Xu. (2019) Association of Craving and Depressive Symptoms in Ketamine‐Dependent Patients Undergoing Withdrawal Treatment. The American Journal on Addictions 29:1, pages 43-50.
Crossref
Crossref
Simone B. Sartori & Nicolas Singewald. (2019) Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders. Pharmacology & Therapeutics 204, pages 107402.
Crossref
Crossref
Elham Sharafi, Arsia Taghva, Mohammad Arbabi, Afsaneh Dadarkhah & Jamshid Ghaderi. (2019) Transcranial Direct Current Stimulation for Treatment-Resistant Major Depression: A Double-Blind Randomized Sham-Controlled Trial. Clinical EEG and Neuroscience 50:6, pages 375-382.
Crossref
Crossref
Philip Brenner, Lena Brandt, Gang Li, Allitia DiBernardo, Robert Bodén & Johan Reutfors. (2019) Treatment‐resistant depression as risk factor for substance use disorders—a nation‐wide register‐based cohort study. Addiction 114:7, pages 1274-1282.
Crossref
Crossref
Mohaddeseh Ebrahimi-Ghiri, Mohammad Nasehi & Mohammad-Reza Zarrindast. (2019) Anxiolytic and antidepressant effects of ACPA and harmaline co-treatment. Behavioural Brain Research 364, pages 296-302.
Crossref
Crossref
Fatemeh Khakpai, Mohaddeseh Ebrahimi-Ghiri, Sakineh Alijanpour & Mohammad-Reza Zarrindast. (2019) Ketamine-induced antidepressant like effects in mice: A possible involvement of cannabinoid system. Biomedicine & Pharmacotherapy 112, pages 108717.
Crossref
Crossref
Emil Trofimiuk, Przemysław Wielgat, Jan J. Braszko & Halina Car. (2019) Stress and Ketamine, Bimodal Influence on Cognitive Functions. Behavioural Brain Research 360, pages 354-364.
Crossref
Crossref
V. D. Mendelevich. (2019) Addictophobia in modern psychiatry (benzodiazepines and other psychopharmacological drugs). Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 119:1, pages 75.
Crossref
Crossref